Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Colorectal Neoplasms 10Esophageal Neoplasms 4Neoplasms 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Oesophago-gastric Cancer 1KRAS and NRAS Wild-type Colorectal Cancer 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Cone Dystrophy 3 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Colorectal Cancer 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × Panitumumab × Clear all
NCT01916109 2016-02-12

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
4 enrolled 6 charts
Genitourinary

Cone Dystrophy 3, Urinary Bladder Neoplasms

NCT01374789 2015-06-03

PURO

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Terminated
2 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡